What SEC filings does Legend Biotech Corporation submit to the SEC?

Legend Biotech Corporation (LEGN) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about LEGN?

A Form 4 for LEGN discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Legend Biotech Corporation?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for LEGN?

The 10-K is Legend Biotech Corporation's annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all LEGN SEC filings directly on EDGAR?

You can view all historical Legend Biotech Corporation filings on the SEC EDGAR company page for LEGN. Each filing card on this page links directly to the original SEC document.

How often does Legend Biotech Corporation file with the SEC?

Legend Biotech Corporation files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling LEGN shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

LEGN SEC Filing News — Legend Biotech Corporation

Latest SEC filings for Legend Biotech Corporation (LEGN) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-01.

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candida…

Sector: Healthcare Industry: Biotechnology Market Cap: $3.7B CIK: 1801198

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for LEGN currently lean bearish. Of the 20 filing records displayed, 5 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

LEGN Filing Activity Snapshot 2026-03-26 — 2026-10-01

Insider Transactions (Form 4)

0 buys vs 5 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$1.30M

Huang Ying · 2026-09-22

69,812 shares · Form 144

Form 144 Notices

Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 14 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 14 filings in this group are Form 4s for Legend Biotech Corporation.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 14 insider filings shown, the breakdown is 8 compensation award, 5 open-market sale and 1 gift. 5 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×8: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market sale ×5: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Gift ×1: Shares were transferred as a gift, typically for estate or charitable planning. No sale into the market took place.

Form 4 Open-market sale Insider Selling 2026-10-01

LEGN insider Sanders Corazon (Corsee) D. (Director) sold 27,370 shares (~$258.9K)

Sanders Corazon (Corsee) D., listed as Director at Legend Biotech Corp, reported an open-market sale of 27,370 LEGN shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	27,370	$9.46	$258.9K

Filing: Form 4 (Insider Transaction) Insider: Sanders Corazon (Corsee) D. (Director) Shares: 27,370 Est. Value: $258.9K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-09-28

LEGN insider Form 4 filed for equity award, exercise, or tax withholding

Salovey Peter (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	28,330	—	—

Filing: Form 4 (Insider Transaction) Insider: Salovey Peter (Director) Shares: 28,330

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-09-28

LEGN insider Form 4 filed for equity award, exercise, or tax withholding

Heyman Tomas J. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	20,986	—	—

Filing: Form 4 (Insider Transaction) Insider: Heyman Tomas J. (Director) Shares: 20,986

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-09-28

LEGN insider Form 4 filed for equity award, exercise, or tax withholding

Mao Li (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	20,986	—	—

Filing: Form 4 (Insider Transaction) Insider: Mao Li (Director) Shares: 20,986

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-09-28

LEGN insider Form 4 filed for equity award, exercise, or tax withholding

Casey Patrick John (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	20,986	—	—

Filing: Form 4 (Insider Transaction) Insider: Casey Patrick John (Director) Shares: 20,986

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-09-28

LEGN insider Form 4 filed for equity award, exercise, or tax withholding

Ji Darren Xiaohui (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	28,330	—	—

Filing: Form 4 (Insider Transaction) Insider: Ji Darren Xiaohui (Director) Shares: 28,330

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-09-28

LEGN insider Form 4 filed for equity award, exercise, or tax withholding

Sanders Corazon (Corsee) D. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	20,986	—	—

Filing: Form 4 (Insider Transaction) Insider: Sanders Corazon (Corsee) D. (Director) Shares: 20,986

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-23

LEGN insider Santos Carlos E (Chief Financial Officer) sold 5,430 shares (~$49.6K)

Santos Carlos E, listed as Chief Financial Officer at Legend Biotech Corp, reported an open-market sale of 5,430 LEGN shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	19,676	—	—
`S`	Open-market sale	5,430	$9.14	$49.6K

Filing: Form 4 (Insider Transaction) Insider: Santos Carlos E (Chief Financial Officer) Shares: 5,430 Est. Value: $49.6K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-09-16

LEGN insider Form 4 filed for equity award, exercise, or tax withholding

Zhang Ingrid (Chief Executive Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	1,131,860	—	—

Filing: Form 4 (Insider Transaction) Insider: Zhang Ingrid (Chief Executive Officer) Shares: 1,131,860

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-18

LEGN insider Form 4 filed for equity award, exercise, or tax withholding

BASH ALAN (Interim CEO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	4,908	—	—

Filing: Form 4 (Insider Transaction) Insider: BASH ALAN (Interim CEO) Shares: 4,908

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-02

LEGN insider Casey Patrick John (Director) sold 6,000 shares (~$88.8K)

Casey Patrick John, listed as Director at Legend Biotech Corp, reported an open-market sale of 6,000 LEGN shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	6,000	$14.80	$88.8K

Filing: Form 4 (Insider Transaction) Insider: Casey Patrick John (Director) Shares: 6,000 Est. Value: $88.8K

View on SEC EDGAR → Open Filing Document →

Form 4 Gift Tax / Compensation Filing 2026-07-02

LEGN insider Form 4 filed for equity award, exercise, or tax withholding

Huang Ying (Director, Chief Executive Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were transferred as a gift, typically for estate or charitable planning. No sale into the market took place.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`G`	Gift	3,382	—	—

Filing: Form 4 (Insider Transaction) Insider: Huang Ying (Director, Chief Executive Officer) Shares: 3,382

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-06-29

LEGN insider Huang Ying (Director, Chief Executive Officer) sold 5,566 shares (~$82.3K)

Huang Ying, listed as Director, Chief Executive Officer at Legend Biotech Corp, reported an open-market sale of 5,566 LEGN shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	5,566	$14.78	$82.3K

Filing: Form 4 (Insider Transaction) Insider: Huang Ying (Director, Chief Executive Officer) Shares: 5,566 Est. Value: $82.3K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-03-27

LEGN insider Huang Ying (Director, Chief Executive Officer) sold 9,936 shares (~$87.1K)

Huang Ying, listed as Director, Chief Executive Officer at Legend Biotech Corp, reported an open-market sale of 9,936 LEGN shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	9,936	$8.77	$87.1K

Filing: Form 4 (Insider Transaction) Insider: Huang Ying (Director, Chief Executive Officer) Shares: 9,936 Est. Value: $87.1K

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 6 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Legend Biotech Corporation has 6 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-09-29

LEGN Form 144 filed for proposed insider sale by Sanders Corazon (Corsee) D. (13,685 shares) ~$258.9K

Sanders Corazon (Corsee) D. filed a Form 144 with the SEC indicating intent to sell LEGN (Legend Biotech Corp) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Sanders Corazon (Corsee) D. Shares: 13,685 Est. Value: $258.9K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-09-22

LEGN Form 144 filed for proposed insider sale by Santos Carlos E (2,715 shares) ~$50.9K

Santos Carlos E filed a Form 144 with the SEC indicating intent to sell LEGN (Legend Biotech Corp) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Santos Carlos E Shares: 2,715 Est. Value: $50.9K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-09-22

LEGN Form 144 filed for proposed insider sale by Huang Ying (69,812 shares) ~$1.30M

Huang Ying filed a Form 144 with the SEC indicating intent to sell LEGN (Legend Biotech Corp) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Huang Ying Shares: 69,812 Est. Value: $1.30M

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-06-30

LEGN Form 144 filed for proposed insider sale by Casey Patrick John (3,000 shares) ~$88.8K

Casey Patrick John filed a Form 144 with the SEC indicating intent to sell LEGN (Legend Biotech Corp) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Casey Patrick John Shares: 3,000 Est. Value: $88.8K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-06-26

LEGN Form 144 filed for proposed insider sale by Huang Ying (2,783 shares) ~$79.0K

Filing: Form 144 (Proposed Sale Notice) Insider: Huang Ying Shares: 2,783 Est. Value: $79.0K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-03-26

LEGN Form 144 filed for proposed insider sale by Huang Ying (4,968 shares) ~$87.1K

Filing: Form 144 (Proposed Sale Notice) Insider: Huang Ying Shares: 4,968 Est. Value: $87.1K

View on SEC EDGAR → Open Filing Document →

How we classify Legend Biotech Corporation's filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on LEGN. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — LEGN SEC Filings

More Tools for LEGN

LEGN Full Stock Analysis LEGN Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper LEGN analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the LEGN stock analysis page.

LEGN Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer